
Sign up to save your podcasts
Or
Send us a text
Kirk Huntsman, Chairman and CEO of Vivos Therapeutics joins us on this week’s WTR Small-Cap Spotlight following the company announcement of its first known FDA clearance for a medical device in pediatric obstructive sleep apnea. He discusses what the FDA approval means for the millions of US children with this serious health condition. Kirk talks about how the pediatric market fits into Vivos’ new marketing and distribution strategy, as well as the progress with medical-based affiliations.
5
66 ratings
Send us a text
Kirk Huntsman, Chairman and CEO of Vivos Therapeutics joins us on this week’s WTR Small-Cap Spotlight following the company announcement of its first known FDA clearance for a medical device in pediatric obstructive sleep apnea. He discusses what the FDA approval means for the millions of US children with this serious health condition. Kirk talks about how the pediatric market fits into Vivos’ new marketing and distribution strategy, as well as the progress with medical-based affiliations.
1,510 Listeners
3,185 Listeners
224,028 Listeners
1,008 Listeners
657 Listeners
3,372 Listeners
1,764 Listeners
3,071 Listeners
187 Listeners
205 Listeners
90 Listeners
5,225 Listeners
101 Listeners
245 Listeners
2,173 Listeners